{
    "clinical_study": {
        "@rank": "141145", 
        "arm_group": [
            {
                "arm_group_label": "Ingenol mebutate gel 0.05 %", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Ingenol mebutate gel 0.015 %", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen\n      compared to a sequential treatment regimen when two separate areas with AKs (one located on\n      face/scalp and the other located on trunk/ extremities) are treated with ingenol mebutate\n      gel"
        }, 
        "brief_title": "A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must provide informed consent\n\n          -  Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous\n             25 cm2 treatment area on face or scalp\n\n          -  Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous\n             25 cm2 treatment area on trunk or extremities\n\n          -  Subjects at least 18 years of age\n\n          -  Female subjects must be of either:\n\n               1. Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical\n                  history of sterility (e.g. the subject is without a uterus) or,\n\n               2. Childbearing potential, provided there is a confirmed negative urine pregnancy\n                  test prior to trial treatment, to rule out pregnancy.\n\n          -  Female subjects of childbearing potential must be willing to use effective\n             contraception at trial entry and until completion.\n\n        Exclusion Criteria:\n\n          -  Location of the selected treatment areas:\n\n               -  on the periorbital skin\n\n               -  within 5 cm of an incompletely healed wound\n\n               -  within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell\n                  carcinoma (SCC)\n\n          -  Prior treatment with ingenol mebutate gel on face/scalp and on trunk/extremities\n\n          -  Lesions in the selected treatment areas that have:\n\n               -  atypical clinical appearance (and/or,\n\n               -  recalcitrant disease\n\n          -  History or evidence of skin conditions other than the trial indication that would\n             interfere with the evaluation of the trial medication\n\n          -  Use of cosmetic or therapeutic products and procedures which could interfere with the\n             assessments of the selected treatment areas\n\n          -  Clinical diagnosis/history or evidence of any medical condition that would expose a\n             subject to an undue risk of a significant AE or interfere with assessments of safety\n             and efficacy during the course of the trial, as determined by the investigator's\n             clinical judgment.\n\n          -  Anticipated need for hospitalisation or out-patient surgery during the first 15 days\n             after the first trial medication application.\n\n          -  Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel\n\n          -  Presence of sunburn within the selected treatment areas\n\n          -  Current enrolment or participation in an investigational clinical trial within 30\n             days of entry into this trial\n\n          -  Subjects previously randomised in the trial\n\n          -  Female subjects who are breastfeeding\n\n          -  In the opinion of the investigator, the subject is unlikely to comply with the\n             Clinical Study Protocol\n\n        Prohibited Therapies and/or Medications within 2 weeks prior to Visit 1:\n\n          -  Cosmetic or therapeutic procedures within 2 cm of the selected treatment areas\n\n          -  Use of topical keratolytic therapeutic products within 2 cm of the selected treatment\n             areas\n\n          -  Use of topical medicated creams, ointments, lotions, gels, foams or sprays including\n             topical steroids : within 2 cm of the selected treatment areas; artificial tanners:\n             within 5 cm of the selected treatment areas\n\n        Prohibited Therapies and/or Medications: within 4 weeks prior to Visit 1:\n\n          -  Treatment with immunomodulators, cytotoxic drugs or interferon/interferon inducers\n\n          -  Treatment with systemic medications that suppress the immune system\n\n          -  Treatment/therapy with ultraviolet light A (UVA) or ultraviolet light B (UVB)\n\n        Prohibited Therapies and/or Medications within 8 weeks prior to Visit 1:\n\n        - Treatment with 5-fluorouracil (5-FU), imiquimod, topical diclofenac sodium, or\n        photodynamic therapy within 2 cm of the selected treatment areas.\n\n        Prohibited Therapies and/or Medications within 6 months prior to Visit 1:\n\n        - Use of systemic retinoids or biologic/monoclonal antibody therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787383", 
            "org_study_id": "LP0041-64", 
            "secondary_id": "2012-002863-88"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ingenol mebutate gel 0.05 %", 
                    "Ingenol mebutate gel 0.015 %"
                ], 
                "description": "Ingenol mebutate gel 0.05 % (Picato\u00ae) on trunk/extremities either applied simultaneously or sequentially", 
                "intervention_name": "Ingenol mebutate gel 0.05 %", 
                "intervention_type": "Drug", 
                "other_name": "Picato\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Ingenol mebutate gel 0.05 %", 
                    "Ingenol mebutate gel 0.015 %"
                ], 
                "description": "Ingenol mebutate gel 0.015 % (Picato\u00ae) on face/scalp either applied simultaneously or sequentially", 
                "intervention_name": "Ingenol mebutate gel 0.015 %", 
                "intervention_type": "Drug", 
                "other_name": "Picato\u00ae"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Actinic Keratosis", 
            "Ingenol mebutate gel"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Modena", 
                    "country": "Italy", 
                    "zip": "41124"
                }, 
                "name": "Clinica Dermatologica dell'Universit\u00e0 di Modena e Reggio Emilia"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Italy: Agenzia Italiana del Farmaco", 
                "Spain: Agencia Espagnola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Composite Local Skin Reaction (LSR) score 3 days after treatment of each selected treatment area in both treatment groups (simultaneous or sequential)", 
            "measure": "Composite Local Skin Reaction (LSR) score 3 days after treatment of each selected treatment area", 
            "safety_issue": "No", 
            "time_frame": "3 days after treatment of each selected treatment area"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787383"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Complete clearance of Actinic Keratosis lesions (AKs) in each separate treatment area", 
                "measure": "Treatment Satisfaction Questionnaire for Medication (TSQM)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }, 
            {
                "description": "Partial clearance of Actinic Keratosis lesions (AKs) in each separate treatment area defined as 75% or greater reduction in Actinic Keratosis lesions (AKs) from start of treatment to 8 weeks after treatment", 
                "measure": "Treatment Satisfaction Questionnaire for Medication (TSQM)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }, 
            {
                "description": "Percent reduction in number of Actinic Keratosis lesions (AKs) in each separate treatment area", 
                "measure": "Treatment Satisfaction Questionnaire for Medication (TSQM)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}